Danaher (NYSE:DHR) Director Teri List Sells 2,778 Shares

Key Points

• Danaher Corporation Director Teri List sold $586,324.68 worth of stock, reducing their ownership by 11.81% to a total of 20,751 shares.
• The company's shares traded down to $207.89, with a 12-month range between $171.00 and $279.90.
• Analysts have set a consensus target price of $247.61 for Danaher, with a majority rating it as a "Moderate Buy".

Danaher Corporation (NYSE:DHR - Get Free Report) Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Danaher Trading Up 0.4%

NYSE:DHR traded up $0.80 during midday trading on Friday, hitting $206.09. 1,979,809 shares of the company traded hands, compared to its average volume of 3,319,294. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The firm's fifty day moving average is $201.65 and its 200-day moving average is $199.51. The firm has a market capitalization of $147.57 billion, a P/E ratio of 43.85, a P/E/G ratio of 2.86 and a beta of 0.73. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. WFA of San Diego LLC purchased a new position in Danaher during the 2nd quarter worth $26,000. Heck Capital Advisors LLC purchased a new position in Danaher during the 4th quarter worth $27,000. Howard Hughes Medical Institute purchased a new position in Danaher during the 2nd quarter worth $27,000. Finally, Sierra Ocean LLC grew its stake in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after buying an additional 76 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

DHR has been the subject of several analyst reports. Evercore ISI lowered their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft reduced their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. UBS Group reduced their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a report on Friday, July 11th. Finally, Wells Fargo & Company reduced their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.